Luspatercept is a medication being studied for its ability to help people with a type of blood disorder called myelodysplastic syndromes (MDS). This disorder can cause anemia, which means the body doesn’t have enough healthy red blood cells. Luspatercept works by helping the body produce more red blood cells, which can reduce the need for blood transfusions. In this trial, researchers are looking at how well luspatercept can help patients become independent of red blood cell transfusions and increase their hemoglobin levels, which is a protein in red blood cells that carries oxygen.

Epoetin Alfa is another medication used in this study to treat anemia in patients with myelodysplastic syndromes (MDS). It is a type of drug known as an erythropoiesis-stimulating agent (ESA), which means it helps the body make more red blood cells. By increasing the production of red blood cells, epoetin alfa can help reduce the need for blood transfusions in patients with anemia. The trial is comparing the effectiveness and safety of epoetin alfa with luspatercept to see which one is better at helping patients with MDS manage their anemia.

Myelodysplastic syndrome (MDS) – Myelodysplastic syndrome is a group of disorders caused by poorly formed or dysfunctional blood cells. It occurs when something goes wrong in the bone marrow, where blood cells are produced. Over time, the bone marrow becomes less effective at producing healthy blood cells, leading to anemia, infections, or bleeding. The disease progresses as the bone marrow produces more abnormal cells, which can crowd out healthy cells. This can result in a shortage of red blood cells, white blood cells, and platelets. As the condition advances, it may lead to more severe symptoms and complications.